ABCURO
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system. The company was incorporated in 2015 and is based in Newton, Massachusetts.
ABCURO
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Newton, Massachusetts, United States
Country:
United States
Website Url:
http://www.abcuro.com
Total Employee:
1+
Status:
Active
Contact:
(617) 714-9759‬
Email Addresses:
[email protected]
Total Funding:
59.85 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx Sitelinks Search Box
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
Mass General Brigham Ventures
Mass General Brigham Ventures investment in Series A - Abcuro
Hongsen Investment Group
Hongsen Investment Group investment in Series A - Abcuro
RA Capital Management
RA Capital Management investment in Series A - Abcuro
Samsara BioCapital
Samsara BioCapital investment in Series A - Abcuro
Pontifax
Pontifax investment in Series A - Abcuro
Sanofi Ventures
Sanofi Ventures investment in Series A - Abcuro
Kaitai Capital
Kaitai Capital investment in Series A - Abcuro
ShangPharma Innovation
ShangPharma Innovation investment in Series A - Abcuro
Partners Innovation Fund
Partners Innovation Fund investment in Series A - Abcuro
Official Site Inspections
http://www.abcuro.com Semrush global rank: 4.75 M Semrush visits lastest month: 1.97 K
- Host name: 240.146.169.192.host.secureserver.net
- IP address: 192.169.146.240
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Abcuro"
About - Abcuro
Abcuro is developing ABC008 for autoimmune disorders. ABC008 is a monoclonal antibody designed to selectively deplete highly cytotoxic T cells by targeting KLRG1 (killer cell lectin-like …See details»
Abcuro - Crunchbase Company Profile & Funding
Abcuro may be growing as it has recently raised $155 million in a funding round, which is a significant financial indicator of growth. The company was also among the top fundraisers in the biotech industry, indicating strong investor …See details»
Team - Abcuro
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the …See details»
Abcuro Company Profile 2024: Valuation, Funding
Abcuro General Information Description. Developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer. The company uses proprietary analysis of transcription data from human disease to identify …See details»
Abcuro - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Abcuro - Org Chart, Teams, Culture & Jobs - The Org
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune …See details»
Abcuro - Bain Capital Life Sciences
Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly …See details»
Abcuro Company Profile: Overview and Full News Analysis
Abcuro, Inc. is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic …See details»
Board of Directors - Abcuro
Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the …See details»
Abcuro - Contacts, Employees, Board Members, Advisors
Organization. Abcuro . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. ... Abcuro has 6 board …See details»
Abcuro Company Profile - Office Locations, Competitors, Revenue …
Abcuro is a company developing immunotherapies to treat autoimmunity and cancer. It offers a monoclonal antibody ABC008 that depletes cytotoxic T cells by targeting killer cell lectin-like …See details»
Abcuro - Overview, News & Similar companies | ZoomInfo.com
Dec 6, 2023 Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., …See details»
Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of …
NEWTON, Mass., December 06, 2023--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise …See details»
Abcuro Raises $42 Million in Series A-1 Financing, Appoints John B ...
Jan 7, 2021 Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of T and …See details»
Abcuro | The Healthcare Technology Report.
Abcuro is empowering patients with IBM by advancing the clinical development of a novel therapeutic medicine that has the potential to preserve and maintain muscle strength. The …See details»
Abcuro raises $155m from Series B to advance autoimmune pipeline
Furthermore, Abcuro will focus on finishing a Phase I/II clinical study of ABC008 in T cell large granular lymphocytic leukemia (T-LGLL) besides commencing a Phase I/II clinical trial in T and …See details»
Leadership - Abcuro
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the …See details»
Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of ...
Dec 6, 2023 Newton, Massachusetts, December 6, 2023— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and …See details»
Careers - Abcuro
Abcuro, Inc. is a clinical-stage biotechnology company developing protein-based treatments for serious autoimmune and cancer indications modulated by cytotoxic T and NK cells that …See details»